TABLE 1.
Enhancer and promoter activities of the human 5"HS5 LTR, chimpanzee 5"HS5 LTR, and human axin LTR in the (E-P-r)-GFP plasmids and the reference GFP plasmida determined by transient-transfection assays
| Cell lineb | Activityc
|
|||
|---|---|---|---|---|
| Human 5"HS5 | Chimpanzee 5"HS5 | Human axin | GFP | |
| Bewo | 1,014 ± 15 (6.4, 388, 2.4) | 514 ± 28 (5.3, 223, 2.3) | 2,300 ± 450 (11, 795, 3.8) | 1.0 (0.06, 16.4, 1) |
| 293 | 1,920 ± 520 (44, 522, 1.9) | NDd | ND | 1.0 (0.13, 48.3, 1) |
| WRL68 | 623 ± 130 (33.8, 239, 1.6) | 456 ± 60 (21.2, 175, 1) | ND | 1.0 (0.14, 57.5, 1) |
| CFU-E | 374 ± 64 (5.4, 76.4, 1.2) | ND | ND | 1.0 (0, 0, 1) |
| K562 | 248 ± 70∗ (21, 130, 2) | 170 ± 45∗ (23, 80, 1.9) | 176 ± 50∗ (25, 85, 2.2) | 1.0 (0.5, 11, 1) |
| Jurkat | 132 ± 30∗ (25, 184, 1.9) | 60 ± 16∗ (19, 87, 1.5) | ND | 1.0 (0.5, 34, 1) |
| HepG2 | 82 ± 25 (16.5, 429, 1.0) | ND | ND | 1.0 (1.7, 51, 1) |
| H1299 | 24 ± 3 (11.2, 105, 2) | ND | ND | 1.0 (0.9, 27, 1) |
| HeLa | 14 ± 6 (60, 70, 1.6) | ND | 10 ± 2 (50, 70, 1.8) | 1.0 (15, 13, 1) |
See Fig. 5a.
Human primary cells and transformed cell lines used as transfection hosts are as follows: Bewo, placental trophoblasts from choriocarcinoma; 293, transformed embryonic kidney; WRL68, transformed embryonic liver; CFU-E, erythroid progenitor cells from adult peripheral blood; K562, erythroleukemia; Jurkat, acute T-cell leukemia; HepG2, hepatoma; H1299, lung carcinoma; HeLa, cervical carcinoma.
Values marked with an asterisk are means ± standard deviations (n = 4); all other values are arithmetic averages (n = 2). The three numbers in parentheses are, respectively, the percentage of fluorescent cells 48 h after electroporation, the mean fluorescent intensity of the fluorescent cells, and the copy number ratio of the test plasmids in the electroporated cell population relative to the reference GFP plasmid in control transfections.
ND, not determined.